NMS-P937
Onvansertib, also know as NMS-P937, PCM-075 and NMS1286937, is a n orally bioavailable, small-molecule Polo-like kinase 1 (PLK1) inhibitor with potential antineoplastic activity. Polo-like kinase 1 inhibitor NMS-1286937 selectively inhibits PLK1, inducing selective G2/M cell-cycle arrest followed by apoptosis in a variety of tumor cells while causing reversible cell-cycle arrest at the G1 and G2 stages without apoptosis in normal cells. PLK1 inhibition may result in the inhibition of proliferation in PLK1-overexpressing tumor cells. PLK1 is a serine/threonine protein kinase crucial in the regulation of mitosis.
Product Specifications
CAS Number
1034616-18-6
Product Name Alternative
PCM-075 | PCM 075 | NMS1286937
Field of Research
Neuroscience
Purity
>98% (HPLC)
Solubility
DMSO : 21 mg/mL. 39.44 mM
Smiles
CN1CCN (CC1) c1cc (c (cc1) OC (F) (F) F) Nc1ncc2CCc3c (c2n1) n (nc3C (=O) N) CCO
Molecular Formula
C24H27F3N8O3
Molecular Weight
532.52
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
1- (2-hydroxyethyl) -8- ((5- (4-methylpiperazin-1-yl) -2- (trifluoromethoxy) phenyl) amino) -4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
HSGT1 (Ecdysoneless Homolog, ECD, GCR2, hSGT1, Protein Ecdysoneless Homolog, Protein SGT1, SGT1, Suppressor of GCR2) (Azide Free) (MaxLight 550)
